Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: A systematic review of the literature with methodological assessment and meta-analysis

Lung Cancer

Volumn 37, Issue 2, 2002, Pages 115-123

  Berghmans, T ^a   Paesmans, M ^a   Lafitte, J J ^b   Mascaux, C ^a   Meert, A P ^a   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Meta analysis; Small cell lung cancer; Systematic literature review

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; INFECTION RATE; LUNG SMALL CELL CANCER; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

CARCINOMA, SMALL CELL; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036021711     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00082-X     Document Type: Article

References (22)

1. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
2. A method for assessing the quality of a randomised clinical trial
3. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
4. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
5. Lenograstim as support for ACE chemotherapy of small-cell lung cancer. A phase III, multicenter, randomized study
6. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma
7. Randomized trials evaluating radiotherapy adjuvant to chemotherapy for small cell lung carcinoma (SCLC): Qualitative evaluation before metaanalysis. The European Lung Cancer Working Party (ELCWP)
8. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
9. CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer
10. Phase II and III studies with new drugs for non-small cell lung cancer: A systematic review of the literature with a methodology quality assessment
11. Received dose-intensity: A randomied trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
12. The medical review article: State of the science
13. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer
14. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multicenter randomized phase III study
15. A three-arm phase III randomised trial testing accelerated chemotherapy with GM-CSF or cotrimoxazole in extensive disease small-cell lung cancer
16. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
17. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial
18. Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: A long-term follow-up
19. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy
20. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer
21. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients